JP2023534959A5 - - Google Patents
Info
- Publication number
- JP2023534959A5 JP2023534959A5 JP2023502897A JP2023502897A JP2023534959A5 JP 2023534959 A5 JP2023534959 A5 JP 2023534959A5 JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023534959 A5 JP2023534959 A5 JP 2023534959A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer cells
- seq
- fragment
- muc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052599P | 2020-07-16 | 2020-07-16 | |
| US63/052,599 | 2020-07-16 | ||
| PCT/US2021/070881 WO2022016190A1 (en) | 2020-07-16 | 2021-07-15 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534959A JP2023534959A (ja) | 2023-08-15 |
| JP2023534959A5 true JP2023534959A5 (https=) | 2024-06-07 |
Family
ID=79554266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502897A Pending JP2023534959A (ja) | 2020-07-16 | 2021-07-15 | Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265208A1 (https=) |
| EP (1) | EP4182354A4 (https=) |
| JP (1) | JP2023534959A (https=) |
| KR (1) | KR20230116767A (https=) |
| CN (1) | CN117693530A (https=) |
| AU (1) | AU2021310499A1 (https=) |
| BR (1) | BR112023000728A2 (https=) |
| CA (1) | CA3186181A1 (https=) |
| IL (1) | IL299903A (https=) |
| MX (1) | MX2023000784A (https=) |
| WO (1) | WO2022016190A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4676975A1 (en) * | 2023-03-03 | 2026-01-14 | Beone Medicines I GmbH | Muc1 and cd16a antibodies and methods of use |
| AR132043A1 (es) * | 2023-03-03 | 2025-05-21 | Beigene Switzerland Gmbh | Anticuerpos muc1 y métodos de uso |
| WO2025217515A2 (en) | 2024-04-12 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Identification of muc1-c as a target for the treatment of squamous cell carcinomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
-
2021
- 2021-07-15 IL IL299903A patent/IL299903A/en unknown
- 2021-07-15 AU AU2021310499A patent/AU2021310499A1/en active Pending
- 2021-07-15 US US18/005,562 patent/US20230265208A1/en active Pending
- 2021-07-15 WO PCT/US2021/070881 patent/WO2022016190A1/en not_active Ceased
- 2021-07-15 CA CA3186181A patent/CA3186181A1/en active Pending
- 2021-07-15 EP EP21842547.8A patent/EP4182354A4/en active Pending
- 2021-07-15 KR KR1020237005383A patent/KR20230116767A/ko active Pending
- 2021-07-15 MX MX2023000784A patent/MX2023000784A/es unknown
- 2021-07-15 CN CN202180063154.3A patent/CN117693530A/zh active Pending
- 2021-07-15 JP JP2023502897A patent/JP2023534959A/ja active Pending
- 2021-07-15 BR BR112023000728A patent/BR112023000728A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| EP4286410A1 (en) | Single-domain antibody against cd16a and use thereof | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| EP3397645B1 (en) | Variable regions for nkp46 binding proteins | |
| JP6392923B2 (ja) | Ｍｕｃ１＊抗体 | |
| WO2018147245A1 (ja) | 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子 | |
| JP2023539501A5 (https=) | ||
| JP7851303B2 (ja) | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 | |
| IL302278A (en) | Combination treatment | |
| JP2023541473A (ja) | 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用 | |
| US20240002544A1 (en) | Cd28 bispecific antibodies for targeted t cell activation | |
| JP2023534959A5 (https=) | ||
| CN113004408B (zh) | 抗人程序死亡因子-1单克隆抗体 | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| CN111655733A (zh) | 共价多特异性抗体 | |
| CN103025760A (zh) | 人源化egfr抗体 | |
| EP4155318A1 (en) | Bispecific antibody and use thereof | |
| WO2018176992A1 (zh) | 新型双特异性抗体及其用途 | |
| JP2025520678A (ja) | Ｒｏｒ１／ｅｇｆｒ二重特異性抗原結合分子 | |
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| JP2024522116A5 (https=) | ||
| WO2024235317A1 (zh) | 结合lilrb4和cd3的抗体及其用途 | |
| KR20250042908A (ko) | 항-메소텔린 항체 및 이의 용도 | |
| JP5884139B2 (ja) | Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬 | |
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 |